Ignite Creation Date:
2025-12-25 @ 3:18 AM
Ignite Modification Date:
2026-01-25 @ 3:47 PM
Study NCT ID:
NCT05882305
Status:
WITHDRAWN
Last Update Posted:
2024-10-30
First Post:
2023-05-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial
Sponsor:
Kousai Bio Co., Ltd.
Organization:
Study Overview
Official Title:
KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial
Status:
WITHDRAWN
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No Participants Enrolled
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to determine the tolerability and feasibility of KSD-101 in patients with EBV-associated haematologic neoplasms,to observe the characteristics of dose-limiting toxicity (DLT)and to explore the range of effective dose.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: